Pharma Mar, S.A. (PHMMF)
OTCMKTS
· Delayed Price · Currency is USD
80.91
0.00 (0.00%)
May 19, 2025, 4:00 PM EDT
Pharma Mar Revenue
Pharma Mar had revenue of 38.86M EUR in the quarter ending March 31, 2025, with 2.35% growth. This brings the company's revenue in the last twelve months to 175.75M, up 8.39% year-over-year. In the year 2024, Pharma Mar had annual revenue of 174.86M with 10.56% growth.
Revenue (ttm)
175.75M EUR
Revenue Growth
+8.39%
P/S Ratio
8.42
Revenue / Employee
351.49K EUR
Employees
500
Market Cap
1.60B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 174.86M | 16.70M | 10.56% |
| Dec 31, 2023 | 158.15M | -38.19M | -19.45% |
| Dec 31, 2022 | 196.34M | -33.49M | -14.57% |
| Dec 31, 2021 | 229.83M | -40.13M | -14.87% |
| Dec 31, 2020 | 269.96M | 184.14M | 214.57% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| American Oncology Network | 1.76B |
| BioStem Technologies | 332.45M |
Pharma Mar News
- 2 months ago - Pharma Mar SA (PHMMF) Q4 2024 Earnings Call Highlights: Record Profits and Strategic Advances - GuruFocus
- 2 years ago - Pharma Mar, S.A. (PHMMF) Q4 2022 Earnings Call Transcript - Seeking Alpha
- 3 years ago - Pharma Mar, S.A. (PHMMF) Management on Q4 2021 Results - Earnings Call Transcript - Seeking Alpha